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Abstract
We have examined patterns of sequence variability for evidence of linked sequence changes in HIV-1 subtype B protease using translated
sequences from protease inhibitor (PI) treated and untreated subjects downloaded from the Stanford HIV RT and Protease Sequence
Database (http://hivdb.stanford.edu). The final data set size was 648 sequences from untreated subjects (notx) and 531 for PI-treated subjects
(tx). Each subject was uniquely represented by a single sequence. Mutual information was calculated for all pairwise comparisons of
positions with nonconsensus amino acids in at least 5% of sequences; significance of pairwise association was assessed using permutation
tests. In addition pairs of positions were assessed for linkage by comparing the observed occurrences of amino acid combinations to expected
values. The mutual information statistic indicated linkage between nine pairs of sites in the untreated data set (10:93, 12:19, 35:38, 37:41,
62:71, 63:64, 71:77, 71:93, 77:93). Strong statistical support for linkage in the treated data set was seen for 32 pairs, eight involving position
10:7 involving position 71, with the rest being 12:19, 15:77, 20:36, 30:88, 35:36, 35:37, 36:62, 36:77, 46:82, 46:84, 48:54, 48:82, 54:82,
63:64, 63:90, 73:90, 77:93, and 84:90. Most associations were positive, although negative associations were seen for five pairs of
interactions. Structural proximity suggests that numerous pairs may interact within a local environment. These interactions include two
distinct clusters around 36/77 and 71/93. While some of these interactions may reflect fortuitous linkage in heavily treated subjects with
many resistance mutations, others will likely represent important cooperative interactions that are amenable to experimental validation.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Activity of the human immunodeficiency virus type I
(HIV-1) protease is required for the maturation of budding
virions into infectious particles, making this protein an
important target of antiretroviral drugs. Although the use of
protease inhibitors (PIs) does not select for resistance as part
of a fully suppressive regimen, viruses containing protease
mutations conferring drug resistance are at a replicative
advantage when complete suppression is not achieved.
Mutations in protease associated with reduced PI sensi-
tivity are often classified as either primary or secondary.
Primary mutations appear early in the evolution of inhibitor
resistance: the major primary resistance mutations occur at
positions 30, 48, 50, 82, 84, and 90. Although these posi-
tions have varying degrees of specificity for different inhib-
itors, substantial cross-resistance has been reported for most
of them, particularly for positions 84 and 90 (inhibitor
specificity of each of these mutations is reviewed in Hirsch
et al., 2000; Kantor et al., 2001; Resch and Swanstrom,
2000; Shafer et al., 2000). Highly resistant viruses may
accumulate more than one of these mutations, and the evo-
lution to resistance for any one inhibitor can proceed along
several different paths. All of these positions occur near the
substrate-binding cleft of the protease except 90 (Wlodawer
and Vondrasek, 1998) and usually directly reduce inhibitor
binding to protease. In general, mutations conferring signif-
icant resistance are absent in untreated populations; this is
consistent with the idea that these substitutions are them-
selves deleterious to virus replication and are maintained
only in the presence of the inhibitor.
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No single mutation provides high-level resistance, which
is generally attained only following the acquisition of one or
more primary mutations in combination with one or more
“secondary” mutations. Secondary mutations by themselves
can be associated with low-level resistance and are common
polymorphisms in untreated populations (Barrie et al., 1996;
Birk and Sonnerborg, 1998; Kozal et al., 1996; Lech et al.,
1996; Wegner et al., 2000). These latter mutations may
compensate for a reduction in fitness (and enhance resis-
tance) or may further reduce drug sensitivity but with an
additional fitness loss (Mammano et al., 2000; Martinez-
Picado et al., 1999; Resch et al., 2002; Zennou et al., 1998).
Both resistance mutations and other mutations occurring
as part of the natural variability of protease often occur
together at frequencies that would not be predicted accord-
ing to chance; i.e., they covary. Covariation between amino
acid positions in protease can be caused by (i) the specificity
of the compensatory effect of one mutation for another; (ii)
and additive reduction in sensitivity to a particular PI by two
or more mutations in the presence of drug selection; or (iii)
the preexistence of a mutation creating a favorable context
for the emergence of a specific resistance mutation at an-
other position (examples of these phenomena can be found
in Condra et al., 1996; Mammano et al., 2000; Molla et al.,
1996; Rose et al., 1996; Winters et al., 1998).
A number of studies have noted the existence of covaria-
tion between amino acid positions in protease (Jacobsen et
al., 1996; Lech et al., 1996; Leigh Brown et al., 1999; Wu
et al., 2003; Yahi et al., 1999). Data sets containing a
relatively small number of sequences have limited the sen-
sitivity of most of these previous studies for detecting co-
variation. Thanks to the availability of many carefully cu-
rated protease sequences at the Stanford HIV RT and
Protease Sequence Database (Kantor et al., 2001), we have
been able to search for evidence of covariation within a
large data set of protease sequences isolated from both
PI-naive subjects and those who have received PI therapy.
Because covariation can also appear by chance or due to the
recent common ancestry of groups of sequences, we have
incorporated both a rigorous statistical element and phylo-
genetic analyses into our study.
Results and discussion
Initial measurements of amino acid variability among
protease sequences from treated and untreated subjects
Amino acid positions in protease range in variability
from completely conserved to having nonconsensus substi-
tutions in nearly 50% of sequences. We restricted our anal-
ysis to positions containing nonconsensus residues in at
least 5% of sequences. Thirty such “variable” positions
were identified between the two data sets; position 88, a
known resistance-associated position with 4.7% variability
in the tx data set, was also included. Each of these 31
positions was assigned to one of three classes based on the
relative frequency of amino acid substitution in the notx and
tx sets (Fig. 1A). Class I positions were of approximately
the same variability among notx and tx sequences (3%
difference between the two data sets). Class II positions had
different frequencies of substitution between notx and tx
sequences (3% difference between the two data sets) with
substantial variability among notx sequences (5%). In this
class, positions 10 and 71 had the biggest increase in vari-
ability between the two data sets (three to fourfold), while
the other positions differed by less than twofold, with vari-
ability at positions 72 and 77 changing the least (approach-
ing Class I). Class III positions had very little variability in
notx sequences (3%), with greater variability among tx
sequences (Fig. 1A). In this last class, position 20 showed
the greatest variability in the notx data set (approaching
Class II). The results of the covariation analysis will be
discussed below in the context of these three classes. These
31 positions are dispersed throughout the entire protease
structure (Fig. 1B).
Analysis of covariation between positions in protease
using mutual information
There are 465 possible pairwise combinations of the 31
variable positions; to permit a direct comparison of patterns
of covariation within the notx and tx sequence sets, we
calculated mutual information (M) values and uncertainty
coefficients (U) for all 465 combinations of these positions
in both data sets. As noted by Korber et al. (1993), the
magnitude of M alone for any given pair of positions is a
poor indicator of covariability without some measure of
significance, which is the probability that the value of M as
great as that observed for that pair of positions could have
been achieved by chance. Accordingly, we used a permu-
tation test to assess the significance of M for each pair of
positions. An additional statistic, the uncertainty coefficient
(U), was calculated for each pair of positions (Theil, 1972).
U is a measure of the proportional reduction in error (PRE)
in predicting one position based on another position and
ranges from 0 (no correlation) to 1 (perfect correspon-
dence). Tables 1 and 2 list M(x, y), U(xy), U(yx), and P
values of these measures for all pairs of positions reaching
a significance of 104 in the notx and tx sequence sets,
respectively.
To describe the associations between specific amino acid
substitutions, we constructed contingency tables indicating
the number of sequences containing each combination of
amino acids at pairs of positions with significant mutual
information scores (Table 3). The magnitude of the positive
or negative association (i.e., more or fewer sequences than
expected containing the combination, respectively) between
amino acids is indicated by ratios of observed to expected
numbers of sequences. The significance of departures from
expected values was calculated using another permutation
test. For example, the bottom right cell of the first contin-
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gency table (describing 10:91) indicates that 41 sequences
in the notx set contain both L101 and 193L; this combina-
tion was observed in 2.3 times more sequences than ex-
pected and has a significance of P  105 (as indicated by
the asterisk).
There are two important limitations to consider in this
analysis resulting from potential sources of bias in the data
set. First, no attempt has been made to sort the sequences
based on subject treatment. Ideally (for this type of analysis)
a progression of mutations that accumulated during treat-
ment with a single protease inhibitor could be analyzed.
This has been done with smaller numbers of sequences for
a few inhibitors (Condra et al., 1996; Jacobsen et al., 1996;
Leigh Brown et al., 1999; Molla et al., 1996; Patick et al.,
1998), but such data are not available in larger numbers.
Thus the data set as we used it is biased in an uncontrolled
way for the inhibitor used or for the use of multiple inhib-
itors either sequentially or together. The second concern is
that there has been no attempt to look at the addition of
sequential mutations. Our understanding of the resistance
phenomenon incorporates an important temporal aspect to
the accumulation of mutations. In some cases we have tried
to infer a temporal relationship based on asymmetry in the
appearance of single versus double mutations, but this in-
terpretation must be made with caution.
Interactions involving positions with preexisting
variability
Pairs varying together in both sets
The notx set of sequences represents the “natural” vari-
ability in protease; in this background, covariation between
positions can be observed in the absence of the positive
selection imposed on specific residues by protease inhibitor
therapy. As expected, the majority of position-pairs cova-
rying in the notx set showed a similar interaction in the tx
set. The occurrence of similar patterns of covariation in both
sets not only provides independent verification of specific
interactions, but also suggests that certain positions play a
role in general compensatory mechanisms. Pairs of statisti-
cally associated positions appearing in both sets included
35:37, 12:19, 71:93, 15:77, 36:77, 63:64, 77:93, 37:41, and
10:93 (some of these pairs did not achieve the strict signif-
icance cutoffs for both tests, but exhibited similar trends, as
discussed below).
Plausible structural explanations for covariation demon-
strated by a subset of these pairs (35:37, 12:19, 71:93,
15:77, and 36:77) are possible. For example, the E35D
N37D combination occurred around twice as often as ex-
pected in both the notx and the tx sequence sets (Table 3).
N37D appears less often than E35D, suggesting that N37D
is stabilized in the presence of E35D to a greater extent than
the reverse. This is also reflected in the values of U(3537)
and U(3735) for these two positions which are 0.087 and
0.047, respectively, in the tx set (i.e., knowing the compo-
sition of position 37 reduces the uncertainty of position 35
more than vice versa). Positions 35 and 37 are near one
another in the protease structure in the hinge region of the
flap, but the side chains are 5.5 Å apart. E35 forms an ionic
bond with R57. In the context of an E35D mutation, R57
might extend to maintain an interaction with the shorter
aspartic acid side chain; this extension could also bring R57
within bonding distance of the side chain of position 37.
Thus N37D would be stabilized by interacting with R57.
The significance of the interaction between positions 12
and 19 seems to be a need to maintain van der Waals
packing between the most common single substitutions at
these two sites, as the single mutations TI2S:L19 and TI2:
L191 were relatively infrequent, occurring 1.9 and 1.5 fold
less often than expected. In the wild-type structure (Von-
drasek and Wlodawer, 1996) the side chains of 12 and 19,
which project into the solvent from parallel strands of a
-sheet, make van der Waals contacts. The loss of the
methyl group in T12S could be compensated by the repo-
sitioning of the methyl group in L19I in the double mutant.
Although M(15,77) narrowly missed the significance cut-
off in the notx set (P  0.0002), the trend was similar in
both sets, with a strong negative interaction between I15V
and V771 (this combination of mutations occurred 2.6 and
3.4 times less often than expected in the notx and tx sets,
respectively); thus I15V appears in the V77 background but
is suppressed in the V77I background. The closest approach
between these positions is 6.1 Å, so they probably do not
interact directly (Fig. 2A). However, residues 15 and 77
both flank M36, and it is possible that the V77I mutation
pushes M36 into an unfavorable interaction with I15V.
Similarly, the presence of the V771 mutation makes M361
less frequent, likely due to an interaction between the 36 and
77 side chains. The side chain of V77 makes van der Waals
contact with the side chain and backbone of M36. The
M361:V771 double mutation is strongly suppressed, with
the double mutant occurring 3.4- and 3.9-fold less often
than expected in the notx and tx sets, respectively, probably
due to a van der Waals clash (M(36,77) was not significant
in the notx set, but showed a trend with P 0.003). This set
of interactions is illustrated in Fig. 2A.
Two additional pairs of positions (63:64 and 77:93) co-
varied significantly in both sets; another pair, 37:41, covar-
ied significantly in the notx set but narrowly missed our
strict significance cutoff in the tx set (Table 3). There was
no clear physical basis for the covariation displayed by any
of these pairs of positions.
Pairs varying together in the untreated set only
Although pairs covarying in the absence of therapy
might be expected to maintain similar interactions in the
presence of protease inhibitors, we found that some detect-
able associations in the notx set were lost or diminished in
the tx set, including 10:93, 71:93, 71:77, and 62:71. This
could have been due to selection bias or a loss of power in
the smaller tx data set (531 sequences versus 648 in the notx
set). Alternatively, competing interactions or functions
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emerging after the onset of therapy might diminish the
importance of these interactions under selective pressure
from protease inhibitors. This possibility is especially note-
worthy for positions 10 and 71.
The most striking example of this phenomenon occurred
for 71:93. Although the mutual information score describ-
ing this interaction reached significance in both sets, the
value of U(7193), the largest among all pairs in the notx set
Fig. 1. (A) Frequency of nonconsensus amino acid substitution in the notx and tx sequence sets. Positions shown contained at least 5% nonconsensus amino
acids (with the exception of position 88 at 4.7%) and are grouped into three classes from left to right: Class I positions were of approximately the same
variability among notx and tx sequences; Class II positions had different frequencies of substitution between notx and tx sequences with substantial variability
among notx sequences; Class III positions had very little variability in notx sequences, with higher levels of variability among tx sequences. (B) A ribbon
diagram, made with MIDAS (Ferrin et al., 1988), of a substrate complex of the HIV-1 protease dimer (Prabu-Jeyabalan et al., 2000), showing the locations
of the three different classes. Yellow are Class I; blue are Class II, and red are Class III.
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Fig. 2. Examination of sidechains of residues whose physical proximity may explain the associations of their respective mutational patterns. The highlighted
residues are shown in green. Hydrogen or ionic bonds between side chains are shown with black dotted lines. The figures were made with MIDAS (Ferrin
et al., 1988). In each panel the left figure shows the region within the crystal structure of a substrate complex (Prabu-Jeyabalan et al., 2000) and the right
figure is a model with the most common mutations replaced at their respective sites using MIDAS. When necessary, side chains were rotated to alleviate a
strong van der Waals clash. (A) Interactions among hydrophobic residues within the core of each monomer, including I15V, K20R, M36I, and V77I. The
close proximity of these side chains could account for the interdependency of the mutational patterns. (B) L10I may act to prevent R8 from interacting with
E21, especially in the context of either V82A and I84V. The catalytic aspartic acid residues are shown in yellow. (C) A71V, G73S, L90M, and I93L, all pack
around the alpha helix, and the interdependence of the mutations may indicate a need to preserve the conformation of this region.
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at 0.163, was reduced by almost a factor of 5 in the tx set.
In addition, the interaction between specific amino acids
was significant only in the notx set, in which A71V was
overrepresented in the 193L background by more than
threefold (A71T193L was also overrepresented, but not
significantly). It is possible that the lengthening of the side
chain of 71 by A71T or A71V is better accommodated by a
leucine than an isoleucine at position 93 (Fig. 2C).
Similarly, no significant covariation was observed for
10:93, 71:77, or 62:71 in the tx set, despite significant
interactions in the untreated set. None of these pairs contain
positions that are near each other in the protease structure
(Fig. 1B).
Pairs varying together in the treated set only
A final set of pairs involving positions that exhibit sub-
stantial variability in the notx set (i.e., Class I and Class II)
covary only in the treated set, suggesting that their interac-
tion is dependent on selective pressure from inhibitor ther-
apy. These pairs include 10:71, 35:36, and 36:62. The
E35D:M361 combination appeared 1.9 times more often
than expected among tx sequences. These side chains lie on
opposite sides of the loop at the hinge of the flap, but do not
directly interact. In addition, L101:A71V and M361:162V
each appeared 1.8-fold over expected values in the tx set.
Neither of these pairs contains positions that are close in the
structure and both positions are fairly variable, especially in
the tx data set, making it difficult to assess the possible
significance of these interactions. An alternative explana-
tion for their statistical association is that these positions are
independently selected through interactions with other po-
sitions and thus appear linked.
Table 1
Results of tests for covariation among amino acid positions in protease exhibiting variability in the notx data set
p2 dist c1 c2 Drug-naı¨ve subjects (notx) Treated subjects (tx)
M U(12) U(21) p(M) p(E) M U(12) U(21) p(M) p(E)
19 3.7 1 1 0.066 0.107 0.132 * * 0.09 0.175 0.186 * *
77 6.1 1 2 0.02 0.046 0.029 0.0002 0.00009 0.028 0.058 0.04 * *
37 4.8 1 1 0.054 0.081 0.043 * * 0.059 0.087 0.047 * *
77 3.4 2 2 0.027 0.054 0.04 0.00304 0.00004 0.061 0.085 0.088 * *
41 9.9 1 1 0.05 0.039 0.085 * 0.00002 0.044 0.035 0.078 0.00032 *
64 1.3 2 1 0.104 0.076 0.149 * * 0.087 0.074 0.127 * *
93 17.9 2 2 0.046 0.068 0.072 * * 0.029 0.042 0.041 0.00004 0.00001
93 10.5 2 2 0.046 0.081 0.071 * * 0.028 0.026 0.041 0.00208 0.00001
71 4.0 2 2 0.021 0.04 0.062 0.00008 0.00003 0.017 0.027 0.018 0.1564 0.00099
77 14.0 2 2 0.032 0.097 0.048 * * 0.014 0.014 0.02 0.46496 0.012
93 4.4 2 2 0.055 0.163 0.086 * * 0.032 0.033 0.046 0.00004 0.00018
71 15.4 2 2 0.011 0.019 0.032 0.2706 0.00966 0.081 0.074 0.083 * *
36 1.3 1 2 0.025 0.037 0.049 0.00348 0.00219 0.066 0.098 0.093 * *
62 7.5 2 2 0.016 0.033 0.031 0.01292 0.00574 0.053 0.074 0.082 * *
Note. Pairs of positions shown received scores for M that were larger than expected with a significance of P  104 in at least one set of sequences.
Columns are defined from left to right as follows: p1, p2, the positions compared, dist, atomic distance in angstroms of closest approach between positions
p1 and p2 calculated from PDB 1A30 (pairs with dist  5.1 Å shaded black); c1, c2, the designated classes of p1 and p2 based on Fig. 2A; M, mutual
information score; U(12), U(21), the uncertainty coefficient for position p1 given position p2, and p2 given p1, respectively; p(M), the probability that the
observed value of M was due to chance; p(E), the lowest probability that the difference between observed and expected counts of a combination of amino
acids represented at a pair of positions was due to chance (see Table 3). An asterisk (*) indicates P  105. Cells containing values corresponding to M,
U, and p(M) are shaded if p(M)  104, likewise, cells corresponding to p(E) are shaded if p(E)  104.
Table 2
Results of tests for covariation between pairs of amino acid positions in
protease in which at least one position varied in the tx set only (i.e.,
Class II/Class III and Class III/Class III interactions)
p2 dist c1 c2 M U(12) U(21)
46 21.8 2 3 0.079 0.072 0.096
48 18.0 2 3 0.039 0.035 0.155
54 16.2 2 3 0.116 0.106 0.177
73 18.9 2 3 0.071 0.065 0.124
82 5.0 2 3 0.121 0.11 0.146
84 7.7 2 3 0.045 0.041 0.121
90 10.0 2 3 0.054 0.05 0.081
36 3.5 3 2 0.104 0.191 0.145
71 21.1 3 2 0.091 0.139 0.093
90 11.5 2 3 0.071 0.06 0.105
73 4.5 2 3 0.093 0.095 0.162
82 17.3 2 3 0.105 0.107 0.126
84 11.7 2 3 0.046 0.047 0.124
90 6.7 2 3 0.112 0.114 0.167
88 3.5 3 3 0.027 0.103 0.114
82 14.2 3 3 0.056 0.068 0.068
84 11.4 3 3 0.035 0.043 0.094
54 5.1 3 3 0.091 0.362 0.138
82 12.0 3 3 0.046 0.184 0.056
82 8.0 3 3 0.23 0.35 0.277
90 8.9 3 3 0.118 0.207 0.176
90 7.1 3 3 0.051 0.137 0.076
Note. Column labels are as defined in the legend for Table 1. P values
are not shown; the significance of both M and E for all pairs shown
achieved P  105 except for M(10,84) and M(30,88), for which P values
were 0.00004 and 0.00008, respectively.
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Table 3
Contingency tables for selected pairs of positions
Note. The identity of the pair of positions is indicated in bold in a box at the top left of each table. Row and column labels in each contingency table indicate
a specific amino acid followed by its overall frequency at that position in square brackets. Rows and columns contain amino acids at each of the two positions
being compared in descending order of abundance; thus the first row and column of each table corresponds to the consensus amino acids. Each cell of the
table contains the three following values: (i) the observed count of sequences containing the indicated combination of amino acids; (ii) in parentheses, the
ratio of observed (obs) to expected (exp) counts of sequences calculated as obs/exp if obs  exp and 1  exp/obs if exp  obs (hence negative values
indicate fewer sequences containing this combination of amino acids than expected. If either value is 0, the raw count values are shown instead); (iii) the
uncorrected p value describing the significance of the difference between the observed and expected values. An asterisk (*) indicates P  105. The
contingency table describing the amino acid composition of positions 10 and 93 in the notx set (top left of the page) is annotated. For example, the bottom
right cell of the first contingency table (describing 10:91) indicates that 41 sequences in the notx set contain both L10I and 193L; this combination was
observed in 2.3 times more sequences than expected and has a significance of P  105 (as indicated by the asterisk). Rows or columns not containing at
least one amino acid combination with P  0.001 are not shown, nor are individual P values  0.001.
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Pairs involving at least one Class III position
The majority of position linkages identified, and those
with the greatest overall magnitude and significance, in-
volved Class III positions, i.e., positions which were vari-
able only in the treated set (Tables 2 and 3).
Interactions involving Class II positions: 10, 36, 71, and
63
Positions 10 and 71 are statistically linked with a number
positions, most of which are not nearby in the structure.
Mutations at both positions 10 and 71 frequently appear in
clinical samples from subjects who have failed protease
inhibitor therapy, and these mutations can be selected by
passage of HIV-1 in the presence of a protease inhibitor in
vitro (Gong et al., 2000; Patick et al., 1996; Smidt et al.,
1997; Vaillancourt et al., 1999; Watkins et al., 2003). Mu-
tations at either one of positions 10 and 71 have previously
been shown to rescue or improve the infectivity of viruses
carrying other mutations associated with protease inhibitor
resistance (Mammano et al., 2000; Nijhuis et al., 1999; Rose
et al., 1996). The association of these positions with a broad
array of other substitutions in the tx data set (10 with 46, 48,
54, 71, 73, 82, 84, 90, and 93; and 71 with 10, 54, 73, 82,
84, 90, and 93) suggests that both may function as compen-
satory mutations through an indirect mechanism. Similar to
other Class II positions, substantial variability is present at
10 and 71 in the notx data set; however, the especially large
increase in variability at these positions in the tx set distin-
guishes these two positions from the others in this class
(Fig. 1A).
L10I is associated with a number of different residues.
However, these interactions are complicated by the accu-
mulation of multiple mutations during the selection for
higher levels of resistance. Virtually all of the examples of
L10I in the Treated data set are in the background of active
site mutations at position 82 and/or 84. Both the L10I:V82A
and the L10I:I84V combinations occur about twice as often
as expected (Table 3). One structural explanation for the
statistical association between 10 and 82/84 is as follows:
R8 forms a conserved ionic bond with D29 at the base of the
active site. Flanking R8, L10, together with L23, V82 and
184, form a hydrophobic barrier. On the other side of this
barrier is the electronegative E21. The loss of hydrophobic
surface when either V82A or 184V mutations occur could
cause an opening in this barrier which may allow increased
interaction between the side chains of R8 and E21, poten-
tially disrupting the active site (Fig. 2B). The L10I mutation
may provide steric interference to E21, preventing it from
adopting a conformation that would allow it to attract the
positively charged R8 and therefore compensating for the
loss of hydrophobic surface resulting from a mutation at 82
or 84.
The apparent association of position 10 with mutations at
positions 46, 48, 54, 73, and 90 may reflect either a more
specific interaction with mutations at 82 or 84, with which
many positions covary, or may reflect a general effect of
fitness enhancement by changes at position 10 in the pres-
ence of resistance mutations. The role of L10I as a general
enhancer could also explain its appearance in the untreated
data set in which mutations at positions 82 and 84 are rare.
Like L10I, A71V is associated with specific changes at a
number of different positions. It is difficult, therefore, to
distinguish specific associations from a more general effect
on protease activity. There is one example of specificity in
the pattern of A71V associations that is suggested by struc-
tural proximity involving positions 73, 90, and 93. A71V
shows an association with both G73S and L90M. In addi-
tion, both G73S and G73T were overrepresented in an
L90M background (by 2.8- and 3.3-fold, respectively); the
statistical correlation between these two Class III positions
was among the strongest seen. Two-thirds of all occurrences
of G73S in the tx set were in an A71V/L90M background,
10-fold above the expected number. Thus, while A71V may
have a more global effect on enzyme activity, the effect on
L90M is likely to be enhanced by the presence of the G73S
mutation. Covariation between positions 71 and 90 (Jacob-
sen et al., 1996; Yahi et al., 1999) and 71 and 82 (Jacobsen
et al., 1996; Leigh Brown et al., 1999) has been described.
Neither A71V nor G73S makes direct contact with the
L90M side chain. However, residues 71 and 73 are located
on a strand adjacent to the helix containing 90 and 93. An
L90M mutation results in an increase in the size of the
residue, and an expansion of this region by this substitution,
might be stabilized from the other side of this helix by
A71V and G73S substitutions. The replacement of G73
with either Ser or Thr introduces a hydroxyl group that is in
a position to interact with the side-chain amines of positions
N88 and Q92. Most mutations at 73 occur in the background
of L90M mutations, suggesting that they are compensatory
for L90M. The new 73/88/92 interactions may increase the
stability of the alpha helix to allow it to accommodate the
larger L90M residue. A71V could provide stability to the
helix by packing against the base of the helix; a resulting
clash with I93 might select for the I93L mutation (Fig. 2C).
Like certain mutations at 10 and 71, P63 has been shown
to have an effect on protease activity and also to act as a
compensatory mutation for some distal protease inhibitor
resistance mutations: P63 is known to have a positive im-
pact on the fitness of a virus carrying D30N and L90M
(Martinez-Picado et al., 1999) and confers modest resis-
tance to indinavir and nelfinavir in combination with other
substitutions (Ziermann et al., 2000). Consistent with these
previous observations, we detected a negative interaction
between P63L and L90M, indicating the importance of P63
in the presence of resistance mutations. Although it has been
reported that a crystal structure of protease containing M46I
and P63 exhibited conformational differences in the flap
region compared to the “wild-type” protein (Chen et al.,
1995), the specific mechanism by which P63 influences
protease activity is unknown. Note that although the wild-
type amino acid at position 63 has historically been consid-
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ered Leu, the consensus was clearly Pro in both data sets:
the notx and tx sequence sets contained P63 in 54 and 69%
of sequences, respectively, compared to 27 and 15% for
P63L; other studies have also noted that Pro is the most
abundant amino acid at position 63 among sequences from
PI-naive subjects (Kozal et al., 1996; Shafer et al., 1999). It
will be important to determine the mechanism by which
mutations at positions 10, 71, and 63 modify protease ac-
tivity in the presence of a wide array of other mutations.
Another instance of covariation in this group appears to
have a structural basis: the side chains of K20 and M36
appear to interact (over 115). In the K20R:M36I double
mutant, the longer Arg side chain would compensate for the
shorter Ile side chain, allowing these two residues to main-
tain an interaction (Fig. 2A). The K20R substitution rarely
occurs in the absence of M361, while the reverse is not true,
suggesting that the latter change precedes the former.
Class III/Class III interactions
Class III mutations are those most strongly associated
with resistance. While the detected interactions are statisti-
cally supported, other important interactions are likely not
included due to the bias of the data set for isolates obtained
following therapy failure with only a subset of the available
protease inhibitors. It is also possible that some of the
interactions detected in the current data set will not be
selected as paired mutations with newer inhibitors even
though one of the mutations is selected. Thus it will be
important to determine the relevance of these and other
interactions as data become available for the newer inhibi-
tors. The current data set is dominated by sequences from
subjects who failed therapy with saquinavir, ritonavir, and
indinavir with a smaller component of nelfinavir failures.
Covariation between positions 30 and 88 in the tx data
set is likely an extreme example of an inhibitor-specific
interaction. Among subjects treated with currently available
protease inhibitors, the D30N mutation is found only in
those receiving nelfinavir (Kantor et al., 2001). In the tx set,
half of all N88D mutations were in the D30N background,
consistent with a previous report that most isolates from
subjects failing nelfinavir therapy containing N88D usually
contained D30N as well (Patick et al., 1998). Thus the
association of D30N and N88D likely represents an en-
hancement of the D30N effect. The D30N mutation reduces
a hydrogen bond with bound nelfinavir (Kaldor et al., 1997).
N88D may contribute to nelfinavir resistance by further
drawing the position 30 side chain away from the vicinity of
the active site and the inhibitor, or by compensating for the
loss of the negative charge on the side from the D30N
mutation, which could affect the long-range electrostatics of
the enzyme. N88S can also serve as a primary resistance
mutation for nelfinavir and other protease inhibitors (Gong
et al., 2000; Smidt et al., 1997; Ziermann et al., 2000). The
observation that no examples of N88S were found with
D30N (data not shown) suggests that N88D and N88S
contribute to resistance by different mechanisms.
Interactions with position 46 represent another example
of distinct patterns of covariation between different muta-
tions at the same position. M46L is overrepresented three-
fold in a V82A background and is somewhat suppressed
(although not significantly) in an I84V background. In con-
trast, M46I appears 2.6 times more often than expected with
I84V (P  2  105) and appears with V82A at near-
expected frequencies. Conversely, nearly half of the I84V
mutations in the data set appear with M46I. Position 46 is
not near the active site residues 82 and 84, and thus the
physical basis for this interaction is unclear. Indeed, it is
likely that M46I and V82A/I84V owe their association to a
general effect of the former mutation: an M46I mutant
exhibited enhanced catalytic activity over the wild-type
enzyme and improved the activity of a protease mutant
containing both V82T and I84V (Schock et al., 1996). A
different combination of mutations at 46 and 82, M46F and
V82I, has also been reported to occur together more often
than expected (Lech et al., 1996).
The pattern of codon usage at position 46 provides evi-
dence that M46I and M46L lie along divergent evolutionary
pathways, and that neither mutation typically gives rise to
the other. Isoleucine, present in 18.5% of tx sequences, is
always encoded by ATA, presumably the result of a third-
position G-to-A transition from the wild-type ATG (methi-
onine). Leucine, present in 8.2% of sequences, is encoded
by TTG (6.8% of sequences), CTG (1.1%), or TTA (0.3%).
Only the rare TTA codon is likely to arise from isoleucine;
TTG and CTG probably result from first-position transver-
sions from the consensus ATG. Thus neither M46I nor
M46L typically serve as intermediates for each other in a
stepwise trajectory to high-level resistance.
Positions 48, 54, and 82 represent a hierarchy of inter-
actions. V82A is a common initial mutation for indinavir
and ritonavir, and the subsequent addition of 154V is fre-
quently seen, particularly in the evolution of resistance to
ritonavir (Condra et al., 1996; Molla et al., 1996). Covaria-
tion between positions 54 and 82 has been reported among
sequences from subjects treated with indinavir (Leigh
Brown et al., 1999) and unspecified combination therapy
(Yahi et al., 1999). The G48V mutation was first described
as being associated with resistance to SQV (Jacobsen et al.,
1996). In this data set, G48V mutations are overrepresented
in the background of V82A and both 154V (narrowly miss-
ing our strict significance cutoff at P  0.0002) and 154T.
The 48:54 and 54:82 interactions were characterized by the
highest values of U seen in this study. Because most 154V
mutations occur in the absence of a G48V change, the latter
is likely a late mutation added after changes at both 54 and
82 have occurred.
In contrast to 154V, all 10 examples of 154T mutations
occur with G48V (and V82A), suggesting that the interac-
tion of I54T with G48V is different than that of 154V. The
addition of a hydroxyl group with the 154T mutation has the
potential to provide backbone interactions at G49 and I47
and likely confers added bridging stability to the antiparallel
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-strands of the flap. The structure of the flap is likely to be
somewhat perturbed by G48V as it slightly displaces F53,
which normally packs against, and likely stabilizes, the
outer surface of the flap.
Finally, I84V and L90M are associated. This association
was noted previously among sequences from subjects
treated with saquinavir (Jacobsen et al., 1996). L90M is an
initial mutation in the evolution of resistance to SQV (Ja-
cobsen et al., 1996), but its structural contribution is poorly
understood. Changes at position 90 also occur in conjunc-
tion with therapy with most currently available protease
inhibitors (reviewed in Shafer et al., 2000). I84V appears
predominately in the L90M background, suggesting that
L90M typically precedes I84V.
A recent study by Wu et al. (2003) has described co-
variation between positions in protease using different sta-
tistical methods; the results of that study are mostly in
agreement with those reported here, particularly for the
most strongly linked positions. A consistent feature of both
studies is the extensive covariation between positions that
are not close enough for a direct physical interaction. Al-
though these authors tested the hypothesis that the covaria-
tion between physically distant positions could be explained
by a chain of covarying residues, they reported that all
potential chains that were identified could have been ex-
plained by chance. Thus the mechanism of the selective
pressures responsible for covariation between distant posi-
tions in protease remains an open question.
Summary
In summary, we have used statistical tools to find sig-
nificant associations between pairs of variable positions in
HIV-1 protease sequences. Some associations are not af-
fected by the presence of resistance mutations, some exist
only as resistance mutations, and other associations appear
to be obscured or lost when resistance mutations are present.
Interactions around residues 36 and 77 and also around 71
and 93 represent distinct but linked clusters that may be
important for regulating protease activity. We have pro-
vided a structural interpretation for many of these interac-
tions, although not all of the interactions lend themselves to
such an interpretation. Overall, this analysis provides a
framework for a systematic characterization of the role of
individual and linked amino acid changes in the evolution of
resistance to protease inhibitors.
Materials and methods
All subtype B protease amino acid sequences from the
Stanford HIV RT and Protease Resistance Database (Kantor
et al., 2001) that had corresponding nucleotide sequences
were downloaded on February 2, 2002. Most (approximate-
ly 75%) of downloaded sequences were identified as mo-
lecular clones in the database; to insure that other sequences
were not derived from viral populations containing complex
mixtures of pro genotypes, we excluded sequences contain-
ing more than two ambiguous codons. In the final data sets,
no position contained an ambiguous codon in more than
2.5% of sequences. Sequences were classified as originating
from subjects who had never received protease inhibitors
(notx) or from those who had been treated with at least one
protease inhibitor (tx). All but one representative of sets of
identical amino acid sequences were discarded, and one
sequence from each subject represented in the database was
chosen at random. The resulting data sets contained 648 and
531 notx and tx sequences, respectively, and are available
from the authors.
A total of 31 positions within protease was analyzed,
based on the presence of a nonconsensus substitution in at
least 5% of sequences in at least one of the sequence sets
(position 88 was also included). Mutual information (M)
was calculated for all possible 465 pairwise combinations of
these 31 variable positions. This statistic has been used as a
measure of covariation in the V3 region of envelope (Bickel
et al., 1996; Korber et al., 1993) and protease sequences
from patients treated with indinavir (Leigh Brown et al.,
1999). M is the sum of the Shannon entropies at each of two
positions minus the joint entropy of the two positions:
M x, y  H x  H y  H x, y
where










P xi, yjlogP xi, yj
Here m and n are the numbers of different amino acids
represented at positions x and y, respectively. P(xi) is the
frequency of amino acid i at position x, and P(xi, yj) is the
frequency of each combination of amino acids xi and yj. If
the amino acids at the two positions vary independently they
will form many combinations and H(x, y) will be large,
reducing the value of M(x, y), if the positions covary, there
will be fewer combinations, and M(x, y) will remain rela-
tively large (since H(x, y) is small). The significance of M
was determined using a permutation test, in which the col-
umns of positions are shuffled in place (breaking any asso-
ciation between the positions) and M(x, y) is recalculated for
each shuffle to generate a reference distribution. Uncor-
rected P values describing the significance of M(x, y) were
calculated as the number of shuffles in which the permuted
value of M was greater than the original value, divided by
the total number of shuffles performed. We used 105 per-
mutations for the test, allowing us to assess significance to
P  0.00001. If no permuted values of M exceeded the
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original value, then P  105. Note that the reference
distribution against which any M(x, y) was compared was
generated from random rearrangements of amino acids in
position x with respect to y. We agree with Bickel et al.,
(1996) that this strategy for calculating significance is rea-
sonable and less likely to exclude weak but real associations
than the approach used in an earlier study (Korber et al.,
1993).
We considered pairs of positions achieving P  104 as
significantly covariant. At this cutoff, the significance level
of the entire analysis (or the probability that at least one of
the 465 possible combinations of 31 positions achieved P 
104 by chance) is 104  465, or less than 0.05 (Bickel
et al., 1996). Fig. 3 shows the distribution of P values of the
465 pairs of positions in the notx and tx sequence sets. Most
comparisons resulted in a P value between 0.1 and 1.0. A
total of 9 (1.9%) and 32 (6.9%) of the 465 possible pairs of
positions reached significance in the notx and tx sequence
sets, respectively. Of these, five pairs were significant in
both sets.
Although this permutation test describes the significance
of an interaction between positions, it does not provide
information about the magnitude of the observed covaria-
tion. Indeed, the correlation between the magnitude of M for
any pair of positions and the significance of that value is
poor (R2  0.26 and 0.33 for the notx and tx sets, respec-
tively). In addition, M is expressed in arbitrary units and
fails to account for differences in variability between posi-
tions and therefore does not provide an easily interpretable
measure of the strength of the interaction between two
positions. Consequently, we also calculated the uncertainty
coefficients U(xy) and U(yx) for each pair of positions
(Theil, 1972)
U xy  M x, y/H x;U yx  M x, y/H y
U(xy) can be interpreted as the proportional reduction in
error in predicting the composition of position x given the
composition of position y. U is an asymmetrical measure
and for positions x and y, U(xy) is often not equal to U(yx).
U is scaled from 0 to 1 and provides a more easily inter-
pretable measure of the strength of the association between
the positions than M. In addition, U also has a somewhat
better correlation with significance than M (R2  0.39 and
0.47 for the notx and tx sets, respectively). The significance
of M(x, y), U(xy), and U(yx) for any x and y are identical,
since the values of H(x) and H(y) are constant in each
permutation.
Neither M nor U describe the underlying linkage be-
tween specific amino acids at a pair of positions. Therefore,
for all pairs of positions achieving a value of M with
significance of P 104 in either the notx or the tx sets (36
pairs), the specific associations among amino acids were
examined in greater detail. For each pair of positions x and
y, the occurrence of each combination of m amino acids at
position x and n amino acids at position y, N(xi, yj) (1 i 
m, 1 j n), was tallied in m n contingency tables. New
contingency tables were then constructed from 105 random-
izations of the data in which all columns of the alignment
were shuffled in place, again with the intention of breaking
any association between each pair of positions. For each
permutation, a new m  n contingency table was calculated
to generate a reference distribution of expected tallies of
each possible combination of amino acids. Combinations of
amino acids at x and y were present either more or less often
than expected, and a significance level, P(xi, yj), was as-
signed to each by counting the number of permuted values
that were either  or N(xi, yj), respectively, and by divid-
ing by the number of permutations. As was the case for M,
some combinations of amino acids were seen either more
rarely or more frequently in the original sequences than in
any of the permutations, resulting in a significance level of
P(xi, yj)  105. For comparison, expected values (E) for
each combination of amino acids at positions x and y were
also calculated as E(xi, yj)  F(xi)F(yj)/N (where F is a
count of sequences containing amino acid xi or yj, and N is
the total number of sequences); E was rounded to the near-
est integer. As expected, E(xi, yj) was approximately equal
to the mean of the reference distribution of permuted values
of N(xi, yj).
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